It has been suggested that atosiban's anti-proliferative effect in some cancer cell lines (including prostate cancer) might be due to a biased agonistic effect where atosiban blocks OT binding to Gαq/11 coupling and thereby promotes OT-coupling to Gαi which leads to inhibition of cell growth (50). Here, OXT is linked to prostate carcinoma.